U.S. study of intravenous mistletoe extract to treat advanced cancer

Researchers completed what is believed to be the first phase I trial of intravenous Helixor M in the U.S. aimed at determining dosing for subsequent clinical trials and to evaluate safety.

Leave a Comment

Your email address will not be published. Required fields are marked *